Theratechnologies Inc. (THTX) NASDAQ
3.39
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Theratechnologies Inc.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
103
First IPO Date
February 13, 2009
Key Executives
| Name | Title | Pay | Year Born |
| Paul Lévesque | President, Chief Executive Officer & Director | 1.29M | 1964 |
| Jocelyn Lafond | General Counsel & Corporate Secretary | 392,072 | 1968 |
| Christian Marsolais | Senior Vice President & Chief Medical Officer | 494,643 | 1963 |
| Philippe Dubuc | Senior Vice President & Chief Financial Officer | 507,441 | 1967 |
| John Leasure | Global Commercial Officer | 581,397 | 1965 |
| Andre Dupras | Vice President of Human Resources | 0 | 1964 |
| Julie Schneiderman | Senior Director, Communications & Corporate Affairs | 0 | N/A |
| Joanne Choi | Senior Director of Investor Relations | 0 | N/A |
Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
